Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults
- PMID: 30607536
- DOI: 10.1007/s00415-018-9160-9
Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults
Erratum in
-
Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.J Neurol. 2019 Apr;266(4):816. doi: 10.1007/s00415-019-09215-1. J Neurol. 2019. PMID: 30759286
Abstract
Objective: To analyze whether myelin oligodendrocyte glycoprotein antibody (MOG-Ab) titres at onset of the disease were different according to the clinical phenotype at presentation, and to investigate whether the titres were associated with risk of further relapses or predicted clinical outcome in adult patients. Finally, we assessed an alternative method to the classical measurement of MOG-Ab levels by serial dilutions.
Methods: This is a retrospective study including 79 MOG-Ab-positive adult patients, whose samples were obtained at first episode. MOG-Ab were tested by cell-based assay. HEK293 cells were transfected (tHEK293) with human-MOG plasmid. Non-tHEK293 cells were used as negative controls. Assessment of antibody titres was performed by serial dilution, and delta mean fluorescence intensity ratio signal (MOG-ratio ΔMFI) by flow cytometry. MOG-ratio ΔMFI was calculated as follows: (MFI tHEK293cells- MFI non-tHEK293cells)/MFI non-tHEK293cells. MOG-ratio ΔMFI was calculated from the first serum dilution at 1:320. The association between MOG-Ab titres and risk of relapse was analyzed by Cox regression. The association between MOG-Ab titres and visual or motor disability at last follow-up was performed by binary logistic regression. Poor visual outcome was defined when patients displayed some degree of visual disability (visual acuity [VA] < 20/20) and poor motor outcome when patients displayed some degree of motor disability (Disability Status Scale [DSS] > 1). We also investigated correlations between MOG-Ab titres and MOG-ratio ΔMFI.
Results: MOG-Ab titres were higher in Caucasians than in those with other ethnicities, and in patients with a more severe VA (VA ≤ 20/100) or motor disability (DSS ≥ 3.0) at onset (p = 0.006, 0.034, and 0.058, respectively). MOG-Ab titres were not associated with risk of relapses or with the final clinical outcome. MOG-ratio ΔMFI correlated with MOG-Ab titres in the whole cohort (ρ = 0.90; p < 0.001), and when stratified by initial clinical phenotype.
Conclusion: High MOG-Ab titres at onset are associated with a more severe presentation, but do not predict the future disease course. MOG-ratio ΔMFI is an alternative and straightforward method to determine MOG-Ab levels.
Keywords: MOG antibodies; Myelitis; Neuromyelitis optica; Optic neuritis; Prognosis; Titre.
Similar articles
-
Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.Ophthalmology. 2018 Oct;125(10):1628-1637. doi: 10.1016/j.ophtha.2018.03.041. Epub 2018 Apr 30. Ophthalmology. 2018. PMID: 29716788
-
Myelin oligodendrocyte glycoprotein antibody-associated demyelination: comparison between onset phenotypes.Eur J Neurol. 2019 Jan;26(1):175-183. doi: 10.1111/ene.13791. Epub 2018 Oct 15. Eur J Neurol. 2019. PMID: 30153357
-
Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.JAMA Neurol. 2014 Mar;71(3):276-83. doi: 10.1001/jamaneurol.2013.5857. JAMA Neurol. 2014. PMID: 24425068
-
MRI features of demyelinating disease associated with anti-MOG antibodies in adults.J Neuroradiol. 2019 Sep;46(5):312-318. doi: 10.1016/j.neurad.2019.06.001. Epub 2019 Jun 20. J Neuroradiol. 2019. PMID: 31228536 Review.
-
Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis.Jpn J Ophthalmol. 2018 Mar;62(2):101-108. doi: 10.1007/s10384-018-0561-1. Epub 2018 Feb 14. Jpn J Ophthalmol. 2018. PMID: 29445944 Review.
Cited by
-
Delimiting MOGAD as a disease entity using translational imaging.Front Neurol. 2023 Dec 7;14:1216477. doi: 10.3389/fneur.2023.1216477. eCollection 2023. Front Neurol. 2023. PMID: 38333186 Free PMC article. Review.
-
Clinical Usefulness of a Cell-based Assay for Detecting Myelin Oligodendrocyte Glycoprotein Antibodies in Central Nervous System Inflammatory Disorders.Ann Lab Med. 2024 Jan 1;44(1):56-63. doi: 10.3343/alm.2024.44.1.56. Epub 2023 Sep 4. Ann Lab Med. 2024. PMID: 37665286 Free PMC article.
-
Dual role of peripheral B cells in multiple sclerosis: emerging remote players in demyelination and novel diagnostic biomarkers.Front Immunol. 2023 Aug 10;14:1224217. doi: 10.3389/fimmu.2023.1224217. eCollection 2023. Front Immunol. 2023. PMID: 37638059 Free PMC article.
-
Clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease according to their epitopes.Front Neurol. 2023 Jun 26;14:1200961. doi: 10.3389/fneur.2023.1200961. eCollection 2023. Front Neurol. 2023. PMID: 37435160 Free PMC article.
-
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges.J Neurol. 2023 Aug;270(8):4132-4150. doi: 10.1007/s00415-023-11737-8. Epub 2023 May 8. J Neurol. 2023. PMID: 37154894 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
